
    
      Surgically treated locally advanced head and neck squamous cell carcinoma often requires
      postoperative chemoradiation with high risk of acute and late toxicity. DFS after 2 years is
      approximately 70%. Combining anti-PD-1 and anti-CTLA4 as a maintenance therapy may improve
      DFS due to anti-tumor effects of immunotherapy by enhancing cross-presentation of tumor
      antigens.
    
  